Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone

BACKGROUND: Daratumumab, pomalidomide, and dexamethasone (DPd) is an effective option for treatment of patients with relapsed/refractory multiple myeloma (RRMM). In this study, we sought to analyze the risk of hematological and non-hematological toxicities in patients who responded to DPd treatment....

Descripción completa

Detalles Bibliográficos
Autores principales: Alkharabsheh, Omar, Bellman, Polina, Mahmoudjafari, Zahra, Cui, Wei, Atrash, Shebli, Paul, Barry, Hashmi, Hamza, Shune, Leyla, Ahmed, Nausheen, Abdallah, Al-Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990715/
https://www.ncbi.nlm.nih.gov/pubmed/36895290
http://dx.doi.org/10.14740/jh1085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990715/
https://www.ncbi.nlm.nih.gov/pubmed/36895290
http://dx.doi.org/10.14740/jh1085

Ejemplares similares